Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Andrei R. Shustov, MD, Bertrand Coiffier, MD, PhD, Steven M. Horwitz, MD, Lubomir Sokol, MD, Ph.D, Barbara Pro, MD, Tina Nielsen, MD, PhD, Julie Wolfson, MPH, Barbara E Balser, VMD, Robin Eisch, RN, Leslie Popplewell, MD, Miles Prince, MD, FRACP, FRCPA, Steven L. Allen, M.D., Richard Piekarz, MD, PhD, Susan E. Bates, MD

Blood (2013) 122 (21): 4385.

https://doi.org/10.1182/blood.V122.21.4385.4385

Published: 2013

Journal Articles

Epigenetic Modulation and Therapy of Lymphoid Malignancies

Susan E. Bates, MD

Blood (2010) 116 (21): SCI-30.

https://doi.org/10.1182/blood.V116.21.SCI-30.SCI-30

Published: 2010

Journal Articles

In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829

Gisela Caceres, Ph.D., Robert W Robey, Ph.D., Lubomir Sokol, MD, PhD, Kathy Rocha McGraw, William J Fulp, Justine Clark, MS, Nicholas J Lawrence, Ph.D., Said Sebti, Ph.D., Susan E. Bates, MD, Alan F. List

Blood (2010) 116 (21): 3986.

https://doi.org/10.1182/blood.V116.21.3986.3986

Published: 2010

Journal Articles

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Richard L. Piekarz, MD PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Laura Hutchins, MD, Louise C. Showe, PhD, William D. Figg, PharmD, Tito Fojo, MD, PhD, Susan E. Bates, MD, for All Collaborators

Blood (2006) 108 (11): 2469.

https://doi.org/10.1182/blood.V108.11.2469.2469

Published: 2006

Journal Articles

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Richard L. Piekarz, MD, PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Susan E. Bates, MD, for All Collaborators

Blood (2005) 106 (11): 231.

https://doi.org/10.1182/blood.V106.11.231.231

Published: 2005

NARROW

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Epigenetic Modulation and Therapy of Lymphoid Malignancies

In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Email alerts

ASH Publications

American Society of Hematology

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Epigenetic Modulation and Therapy of Lymphoid Malignancies

In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only